Global Gastrointestinal Market Revenue to Record 4.45% CAGR to 2020, States GBI Research in In-demand Report Published at MarketPublishers.com
15 Nov 2016 • by Natalie Aster
LONDON – The gastrointestinal marketplace is projected to change considerably with the launch of promising new pipeline products.
With respect to the gastrointestinal pipeline, there are 937 products under active development, with small molecules and biological drugs accounting for 53% and 38%, respectively.
The unmet need and high demand for improved treatment options as well as the high prevalence rate of digestive disorders make the gastrointestinal marketplace an appealing therapeutic development candidate.
Worldwide, the gastrointestinal market revenue is projected to increase from USD 35.7 billion as of 2015 to USD 48.4 billion by 2022-end, demonstrating a 4.45% CAGR. Proton pump inhibitors (PPIs) and tumour necrosis factor-alpha (TNF-α) inhibitors make up the largest portion of total revenues and keep on retaining commercial prominence. The major factors driving the market growth will likely be the uptake of premium products that have been approved recently, surging prevalence, and promising products in late-stage development, including a range of biologic treatments that are anticipated to be of high value.
In-demand study “Global Gastrointestinal Drug Market to 2022” drawn up by GBI Research provides an all-encompassing, trustworthy analysis and forecast of the market. It includes data on the actual clinical and commercial landscape; canvasses the composition of the gastrointestinal market across each of the indications, in regard to major molecule types and targets, limelighting the leading commercial assets and dominant players. The report gives an overview of the gastrointestinal pipeline, dissecting it by development stage, molecule type and target and providing a detailed breakdown across key therapeutic indications. It provides a refined understanding of the growth in patient epidemiology and market revenue for the global gastrointestinal sector and across the leading players and types of products. The publication presents market categorisation based on premium and generic products and evaluates the role of these types of products in the medical treatment of the different gastrointestinal diseases. The study also analyses prevailing trends in co-development and licensing gastrointestinal deals.
More comprehensive market studies by GBI Research are available at its page.